Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...
Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...
- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic filings EAST HANOVER, N.J., August 27, 2008 ...
The team notes, "Taken together, Gleevec exhibits greater beneficial effects on both glucose/lipid metabolism and energy homeostasis by blocking PPARĪ³ phosphorylation." They continue, "These data ...
In a study of patients with chronic myeloid leukemia, some 95 percent have survived the cancer after five years due to treatment with Gleevec, according to results published this week in the New ...
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some ...
After a yearslong court battle, Novartis has prevailed against a pair of class-action lawsuits alleging the company illegally protected its blockbuster leukemia drug Gleevec with "sham" patent ...
In the mid-1990s Mel Mann was counting down his days. His doctor had given him three years to live, and time was running out. Mann's chronic myeloid leukemia diagnosis had prompted him to retire from ...
Gleevec, the cancer "wonder drug" that has proven effective for gastrointestinal stromal tumors might also be useful for Alzheimer's patients, if only one could deliver it to the brain effectively, ...
Novartis boasts an accelerated approval for its Gleevec follow-on drug Scemblix in previously treated chronic myeloid leukemia. Now with new clinical data, the company hopes to turn it into a full nod ...
A drug that has been used to treat thousands of leukemia patients may carry serious heart risks, say researchers. Gleevec is designed to specifically target and prevent cancer cells from multiplying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback